|
Liaoning Pharmaceutical Innovation Co., Ltd.
|
Carbamazepine (CBZ) is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia. It is also used off-label for a variety of indications, including attention-deficit hyperactivity disorder (ADHD), schizophrenia, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, and post-traumatic stress disorder. |
Send Inquiry
|
|
Polpharma
|
Carbamazepine
- Long experience in in-house commercial manufacturing
- High manufacturing capacity
- Improved technology to meet the highest quality standards (all single impurities below 0,06%)
- 3 production lines
| Status |
Commercial |
| Therapeutic cat. |
Neurology |
| Polymorphic form |
Form III |
| CAS No. |
298-46-4 |
| EU DMF readiness |
 |
| CEP |
|
| KOREAN DMF |
|
| US DMF readiness |
|
Drug description
Carbamazepine is an anticonvulsant. It works by decreasing nerve impulses that cause seizures and nerve pain, such as trigeminal neuralgia and diabetic neuropathy. Carbamazepine is also used to treat bipolar disorder. Carbamazepine may also be used for purposes not listed in this medication guide.
Disclaimer: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). |
Send Inquiry
|
Pharma Sources Insight January 2025
